利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

13 条记录 (耗时 0.019 秒)

    Damping device of stay cable
    1.
    发明授权
    Damping device of stay cable 有权
    拉索阻尼装置

    公开(公告)号：US08215607B2

    公开(公告)日：2012-07-10

    申请号：US13178499

    申请日：2011-07-08

    申请人： Zhengxing Wang ,  Cuicui Guo ,  Mingxing Zhou ,  Zhiyang Tong ,  Guiqiong Hu ,  Baohui Cheng ,  Jiwei Zhong ,  Bo Wang ,  Jian Zhao ,  Wu Li

    发明人： Zhengxing Wang ,  Cuicui Guo ,  Mingxing Zhou ,  Zhiyang Tong ,  Guiqiong Hu ,  Baohui Cheng ,  Jiwei Zhong ,  Bo Wang ,  Jian Zhao ,  Wu Li

    IPC分类号： F16M13/00

    CPC分类号： E01D19/16 ,  F16F7/02 ,  F16F7/1022 ,  F16F15/022

    摘要： A damping device for a stay cable including a rotating lever, a lever support saddle, a longitudinal connecting member, and a rigid connection rod. When the stay cable vibrates inside or outside the plane thereof, the vibration displacement is transferred to the rotating lever through the rigid connection rod. One end of the rotating lever is connected to the lever support saddle via the longitudinal connecting member, and can rotate up and down with the lever support saddle as the axis and rotate around its central axis. The other end of the rotating lever is connected to a mass block and a damper. The damping device effectively inhibits vibrations inside and outside the stay cable plane, is easy to install and maintain, and does not negatively impact the appearance of a cable-stayed bridge.

    摘要翻译： 一种用于拉索的阻尼装置，包括旋转杆，杠杆支撑鞍座，纵向连接构件和刚性连接杆。 当拉索在其平面内部或外部振动时，振动位移通过刚性连接杆传递到旋转杆。 旋转杆的一端通过纵向连接构件连接到杠杆支撑鞍座，并且可以以杠杆支撑鞍座作为轴线上下旋转并围绕其中心轴线旋转。 旋转杆的另一端连接到质量块和阻尼器。 阻尼装置有效地抑制了拉索平面内外的振动，易于安装和维护，不会对斜拉桥的外观产生负面影响。

    Stabilized Polymeric Delivery System
    4.
    发明申请
    Stabilized Polymeric Delivery System 有权
    稳定的聚合物输送系统

    公开(公告)号：US20080299168A1

    公开(公告)日：2008-12-04

    申请号：US11667433

    申请日：2005-11-10

    申请人： Eric Dadey ,  Mingxing Zhou

    发明人： Eric Dadey ,  Mingxing Zhou

    IPC分类号： A61K9/00 ,  A61K31/765 ,  A61P43/00

    CPC分类号： A61L27/54 ,  A61K9/0024 ,  A61K9/1647 ,  A61K47/12 ,  A61K47/34 ,  A61L27/58 ,  A61L2300/252 ,  A61L2300/258 ,  A61L2300/604 ,  A61L2300/622

    摘要： The invention relates to a delivery system for the sustained and controlled delivery of a group of bioactive agents. More particularly, the invention relates to a delivery system and a method for delivery of a bioactive agent containing a nucleophilic functional group by means of a biodegradable, sustained-release implant. The implant may be a preformed implant, microparticles or an in situ formed implant. The implant includes a biodegradable thermoplastic polymer, the bioactive agent having a nucleophilic group substituent and a stabilizing associate as well as other optional components. The combination of the stabilizing associate with the bioactive agent prevents and/or minimizes and/or lessens degradation of the thermoplastic polymer by the bioactive agent.

    摘要翻译： 本发明涉及用于持续和控制地递送一组生物活性剂的递送系统。 更具体地，本发明涉及通过可生物降解的持续释放植入物递送含有亲核官能团的生物活性剂的递送系统和方法。 植入物可以是预先形成的植入物，微粒或原位形成的植入物。 植入物包括可生物降解的热塑性聚合物，生物活性剂具有亲核基团取代基和稳定缔合物以及其它任选的组分。 稳定缔合物与生物活性剂的组合防止和/或最小化和/或减少生物活性剂对热塑性聚合物的降解。

    Controlled release liquid delivery compositions with low initial drug burst
    5.
    发明授权
    Controlled release liquid delivery compositions with low initial drug burst 有权
    具有低初始药物爆发的控制释放液体递送组合物

    公开(公告)号：US06630155B1

    公开(公告)日：2003-10-07

    申请号：US09643289

    申请日：2000-08-22

    申请人： Bhagya L. Chandrashekar ,  Mingxing Zhou ,  Eileen M. Jarr ,  Richard L. Dunn

    发明人： Bhagya L. Chandrashekar ,  Mingxing Zhou ,  Eileen M. Jarr ,  Richard L. Dunn

    IPC分类号： A61F200

    CPC分类号： A61K9/0024

    摘要： The invention provides a controlled release polymeric composition which includes a base polymer or copolymer, an organic solvent, a polymeric controlled release additive, and a biologically active agent. The polymeric controlled release additive reduces the initial burst of biologically active agent released from the polymeric composition as it is solidifying to form the solid implant. The controlled release additive is preferably a poly(lactide-co-glycolide)/polyethylene glycol block copolymer.

    摘要翻译： 本发明提供一种控释聚合物组合物，其包含基础聚合物或共聚物，有机溶剂，聚合物控释添加剂和生物活性剂。 当聚合物组合物固化以形成固体植入物时，聚合物控制释放添加剂减少从聚合物组合物释放的生物活性剂的初始爆发。 控释添加剂优选为聚（丙交酯 - 共 - 乙交酯）/聚乙二醇嵌段共聚物。

    Injectable flowable composition comprising buprenorphine
    7.
    发明授权
    Injectable flowable composition comprising buprenorphine 有权
    可注射的可流动组合物包含丁丙诺啡

    公开(公告)号：US08921387B2

    公开(公告)日：2014-12-30

    申请号：US13703013

    申请日：2011-06-06

    申请人： Richard L. Norton ,  Andrew Watkins ,  Mingxing Zhou

    发明人： Richard L. Norton ,  Andrew Watkins ,  Mingxing Zhou

    IPC分类号： A01N43/42 ,  A61K31/44 ,  A61K9/00 ,  A61K31/485 ,  A61K47/34

    CPC分类号： A61K9/0002 ,  A61K9/0024 ,  A61K31/485 ,  A61K47/34

    摘要： The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.

    摘要翻译： 本发明涉及能够在约14天至约3个月的时间内递送丁丙诺啡，代谢物或其前药的丁丙诺啡缓释递送系统。 丁丙诺啡持续释放递送系统包括用于持续释放丁丙诺啡，代谢物或其前药的可流动组合物和固体植入物。 植入物由可流动的组合物制成。 丁丙诺啡持续释放递送系统提供原位1个月和3个月的释放特征，其特征在于具有极高的生物利用度和最小的永久性组织损伤的风险，并且通常没有肌肉坏死的风险。

    Formulations for cell-schedule dependent anticancer agents
    9.
    发明申请
    Formulations for cell-schedule dependent anticancer agents 审中-公开
    细胞计划依赖抗癌剂的制剂

    公开(公告)号：US20060121085A1

    公开(公告)日：2006-06-08

    申请号：US11222668

    申请日：2005-09-09

    申请人： Stephen Warren ,  Eric Dadey ,  Mingxing Zhou ,  Richard Dunn

    发明人： Stephen Warren ,  Eric Dadey ,  Mingxing Zhou ,  Richard Dunn

    IPC分类号： A61K31/7072 ,  A61F2/00 ,  A61K9/14

    CPC分类号： A61L27/54 ,  A61K9/0024 ,  A61K31/7072 ,  A61L27/18 ,  A61L27/50 ,  A61L27/58 ,  A61L2300/416 ,  A61L2300/426 ,  A61L2300/434 ,  A61L2300/602 ,  A61L2300/802 ,  A61L2400/06 ,  C08L67/04

    摘要： The present invention provides a flowable composition suitable for use as a controlled release implant. The composition includes: (a) a biodegradable, biocompatible thermoplastic polymer that is at least substantially insoluble in aqueous medium, water or body fluid; (b) a cell-cycle dependent biological agent, a schedule-dependent biological agent, a metabolite thereof, a pharmaceutically acceptable salt thereof, or a prodrug thereof; and (c) a biocompatible organic liquid, at standard temperature and pressure, in which the thermoplastic polymer is soluble. The present invention also provides a method of treating cancer in a mammal. The present invention also provides a method of blocking, impeding, or otherwise interfering with cell cycle progression at the G1-phase, G1/S interphase, S-phase, G2/M interface or M-phase of the cell cycle in a mammal. The methods includes administering to a mammal an effective amount of a flowable composition of the present invention.

    摘要翻译： 本发明提供适合用作控释剂的可流动组合物。 组合物包括：（a）可生物降解的生物相容性热塑性聚合物，其至少基本上不溶于水性介质，水或体液; （b）细胞周期依赖性生物制剂，计划依赖性生物制剂，其代谢物，其药学上可接受的盐或其前药; 和（c）在标准温度和压力下的热塑性聚合物可溶的生物相容性有机液体。 本发明还提供了一种治疗哺乳动物癌症的方法。 本发明还提供在哺乳动物的细胞周期的G1期，G1 / S间期，S期，G2 / M界面或M期，阻断，阻碍或以其他方式干扰细胞周期进程的方法。 所述方法包括向哺乳动物施用有效量的本发明的可流动组合物。

    Injectable Flowable Composition Comprising Buprenorphine
    10.
    发明申请
    Injectable Flowable Composition Comprising Buprenorphine 有权
    包含丁丙诺啡的可注射流动组合物

    公开(公告)号：US20130210853A1

    公开(公告)日：2013-08-15

    申请号：US13703013

    申请日：2011-06-06

    申请人： Richard L. Norton ,  Andrew Watkins ,  Mingxing Zhou

    发明人： Richard L. Norton ,  Andrew Watkins ,  Mingxing Zhou

    IPC分类号： A61K9/00

    CPC分类号： A61K9/0002 ,  A61K9/0024 ,  A61K31/485 ,  A61K47/34

    摘要： The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.

    摘要翻译： 本发明涉及能够在约14天至约3个月的时间内递送丁丙诺啡，代谢物或其前药的丁丙诺啡缓释递送系统。 丁丙诺啡持续释放递送系统包括用于持续释放丁丙诺啡，代谢物或其前药的可流动组合物和固体植入物。 植入物由可流动的组合物制成。 丁丙诺啡持续释放递送系统提供原位1个月和3个月的释放特征，其特征在于具有极高的生物利用度和最小的永久性组织损伤的风险，并且通常没有肌肉坏死的风险。